Original Article
Use of an Inactivated Varicella Vaccine in Recipients of Hematopoietic-Cell Transplants
N Engl J Med 2002; 347:26-34July 4, 2002
- Abstract
Background
The reactivation of varicella–zoster virus from latency causes zoster and is common among recipients of hematopoietic-cell transplants.
Methods
We randomly assigned patients who were scheduled to undergo autologous hematopoietic-cell transplantation for non-Hodgkin's or Hodgkin's lymphoma to receive varicella vaccine or no vaccine. Heat-inactivated, live attenuated varicella vaccine was given within 30 days before transplantation and 30, 60, and 90 days after transplantation. The patients were monitored for zoster and for immunity against varicella–zoster virus for 12 months.
Results
Of the 119 patients enrolled, 111 received a transplant. Zoster developed in 7 of 53 vaccinated patients (13 percent) and in 19 of 58 unvaccinated patients (33 percent) (P=0.01). After two patients in whom zoster developed before transplantation were excluded, the respective rates were 13 percent and 30 percent (P=0.02). In vitro CD4 T-cell proliferation in response to varicella–zoster virus (expressed as the mean stimulation index) was greater in patients who received the vaccine than in those who did not at 90 days, after three doses (P=0.04); at 120 days, after all four doses (P<0.001); at 6 months (P=0.004); and at 12 months (P=0.02). The risk of zoster was reduced for each unit increase in the stimulation index above 1.6; a stimulation index above 5.0 correlated with greater than 93 percent protection. Induration, erythema, or local pain at the injection site was observed in association with 10 percent of the doses.
Conclusions
Inactivated varicella vaccine given before hematopoietic-cell transplantation and during the first 90 days thereafter reduces the risk of zoster. The protection correlates with reconstitution of CD4 T-cell immunity against varicella–zoster virus.
Media in This Article
Figure 3
CD4 T-Cell Proliferation in Response to Varicella–Zoster Virus Antigen among Recipients of Hematopoietic-Cell Transplants Who Were Randomly Assigned to Receive Inactivated Varicella Vaccine or No Vaccine.Figure 2
Probability of Zoster among Recipients of Autologous Hematopoietic-Cell Transplants Who Were Randomly Assigned to Receive Inactivated Varicella Vaccine or No Vaccine.Article Activity
- Article
Varicella–zoster virus causes chickenpox and becomes latent in sensory ganglia, with an estimated 250 genome equivalents per 100,000 ganglial cells.1-7 When latency is disrupted, the virus is transported along neuronal axons to the skin, resulting in zoster. Since immune surveillance is critical for maintaining latency, zoster is common among immunocompromised patients, including recipients of hematopoietic-cell transplants.8-16 The increased risk of zoster in these patients is associated with diminished T-cell immunity against varicella–zoster virus14,16,17 but not with low titers of IgG antibodies to varicella–zoster virus.18 T-cell immunity against varicella–zoster virus recovers slowly after hematopoietic-cell transplantation and often does not occur without reactivation of the virus,14,16 which usually induces a T-cell response and reestablishment of latency.2
Live varicella vaccines have been licensed for the prevention of varicella.19 These vaccines, as well as a heat-inactivated formulation, have also been found to enhance immunity against varicella–zoster virus in healthy persons.20,21 The inactivated varicella vaccine was immunogenic when three doses were given to a heterogeneous group of patients who had undergone allogeneic or autologous hematopoietic-cell transplantation, but the incidence of zoster was not reduced.22 In this study, we added a fourth dose, given within 30 days before transplantation, and tested only patients with lymphoma who received an autologous hematopoietic-cell transplant. The rationale for this dosing schedule was that T cells specific for varicella–zoster virus might persist, despite the preparatory regimen, if a dose of vaccine was given immediately before transplantation.23-25
Methods
Population
Enrollment was offered to male and female patients 18 to 60 years old who were seropositive for varicella–zoster virus and who had lymphoma and were scheduled for autologous hematopoietic-cell transplantation within the upcoming 30 days. Eligibility criteria included lack of a response, at least once, to standard treatment for Hodgkin's disease or non-Hodgkin's lymphoma or a high risk of early recurrence. Exclusion criteria were a history of zoster within 12 months before the transplantation, exposure to varicella–zoster virus within 4 weeks, administration of another vaccine within 4 months, or neomycin sensitivity.
For patients with non-Hodgkin's lymphoma, the preparatory regimen included total-body irradiation and chemotherapy, whereas patients with Hodgkin's lymphoma received only myeloablative chemotherapy.26-29 Autologous hematopoietic-cell grafts were obtained by apheresis except in four patients with non-Hodgkin's lymphoma, from whom bone marrow was harvested. The grafts were purged with monoclonal antibodies against CD9, CD10, CD19, and CD20 plus rabbit complement.30 The study was approved by the Stanford University institutional review board. Written informed consent was obtained from all the participants.
Study Design
In this randomized trial, the primary end point was the development of zoster within 12 months after transplantation. Eligible patients were enrolled, assigned an anonymous study number, and randomly assigned to receive vaccine (the vaccine group) or no vaccine (the control group). Placebo injections were not used in the control group because the development of zoster is a well-defined clinical end point. Randomization was performed in blocks according to the date of enrollment, and adjustment was made for covariates, including age, diagnosis, health status, and transplantation protocol. The participants and medical personnel were blinded to the randomization process, which was performed by members of the biostatistics core staff at Stanford University.
The study was designed to detect an absolute difference of 20 percentage points (30 percent vs. 10 percent) between the groups in the incidence of zoster; the necessary sample size was calculated to be 58 patients per group to detect such a difference at a one-sided alpha level of 0.05, with 80 percent power. Reconstitution of immunity against varicella–zoster virus was a secondary end point. The severity of zoster was not an end point, because patients received antiviral therapy for episodes of zoster. Our transplantation protocols did not include prophylaxis against varicella–zoster virus; acyclovir prophylaxis was given to patients with antibodies to herpes simplex virus who were given total-body irradiation. Enrollment, data collection, and outcomes were monitored by a data and safety monitoring committee.
Vaccination Regimen
The investigational heat-inactivated varicella vaccine was made from live attenuated varicella vaccine containing 6115 plaque-forming units per 0.5 ml (Varivax, lot no. 1458/W-C471, Merck). The vaccine was stored at –70°C, reconstituted with sterile diluent, and administered as a 0.5-ml dose by subcutaneous injection into the upper arm. A dose was given to patients in the vaccine group within 30 days before hematopoietic-cell transplantation, regardless of the apheresis schedule, and then again 30, 60, and 90 days after transplantation.
The occurrence of local pain, swelling, induration, redness, erythema, bruising, or pruritus was recorded for 21 days. The patients were monitored for survival and disease-related events.
Evaluation for Zoster and Immune Reconstitution
Symptoms of zoster were explained to the patients with the use of pictures of typical rashes. The patients were instructed to report symptoms and were interviewed monthly for four months and then every two months. Zoster was diagnosed if a painful, vesicular rash with a dermatomal distribution developed. The following features were documented: the onset, location, and duration of the lesions; cutaneous dissemination; systemic symptoms; and pain.
Patients in both groups were tested for immunity against varicella–zoster virus within 30 days before transplantation (before the first dose of the vaccine was given) and then again at 30 days after transplantation (before the second dose), at 90 days (after the third dose), at 120 days (after the fourth dose), and at 6 and 12 months. Immunity against varicella–zoster virus was reevaluated after an episode of zoster. The proliferation of T cells specific for varicella–zoster virus was assessed by measuring the uptake of tritiated thymidine by peripheral-blood mononuclear cells and expressed in terms of the stimulation index; the stimulation index was the ratio of mean counts per minute in antigen-containing wells to mean counts per minute in control wells.22,31 The inactivated varicella–zoster virus antigen used for stimulation caused proliferation of CD4 T cells.22 T cells exposed to varicella–zoster virus in vitro were evaluated for the expression of intracellular interferon-γ and tumor necrosis factor α (TNF-α) and for the expression of CD4 and CD69, which is a marker of activated T cells, by flow cytometry (FACS-Calibur, Becton Dickinson Immunocytometry Systems).32 IgG antibodies to varicella–zoster virus were measured by enzyme-linked immunosorbent assay.22
Statistical Analysis
Clinical and immunologic data were reported to the biostatistics core staff according to the patients' study numbers. Immunologic responses and the presence or absence of zoster were monitored for 12 months after transplantation (12.5 months after enrollment); overall survival was recorded until October 31, 2001. The probability of the development of zoster and the probability of survival were estimated with the use of the product-limit method of Kaplan and Meier; the probabilities in the two groups were compared with the use of the log-rank statistic. The unpaired t-test was used to compare the means of logarithms of stimulation indexes; stimulation indexes were reported as means ±SE. The paired t-test was used to compare the pretransplantation and post-transplantation stimulation indexes and titers of IgG antibodies to varicella–zoster virus. All reported P values are two-sided. Local reactions were compared between the groups by means of Fisher's exact test.
The time-varying Cox proportional-hazards model was used to estimate the relation between the occurrence of episodes of zoster and the stimulation index.33 The stimulation index was used as the time-dependent covariate to obtain a risk ratio for zoster per unit increase in the stimulation index. For each patient with zoster, the stimulation index just before the onset of zoster was compared with that of patients without zoster at a similar time point; all the patients with zoster from both the vaccine group and the control group were included in this analysis. In separate analyses, a dichotomous variable was used to evaluate various cutoff values (e.g., a stimulation index of 3.0 or more) as predictors of the risk of zoster. Although the vaccine was supplied by Merck, the study design, accrual, data analysis, and manuscript preparation were carried out by the investigators under the aegis of competitive National Institutes of Health funding.
Results
Characteristics of the Study Population
We enrolled 119 patients from March 1997 to June 2000; 59 patients were randomly assigned to a group that received the vaccine and 60 to a control group, which received no vaccine. Eight patients (six assigned to the vaccine group and two to the control group) did not undergo transplantation. The patients in the two groups were similar with respect to sex, age, diagnosis, and preparatory regimens (Table 1Table 1
Clinical Characteristics of the Patients.), and with respect to clinical indications for transplantation. Three patients in the vaccine group and two in the control group were given acyclovir as prophylaxis against herpes simplex virus infection. In addition, 29 patients in the vaccine group and 28 in the control group received intravenous or oral acyclovir for oral lesions, mucositis, or genital herpes during the first 120 days after transplantation; the dose of intravenous acyclovir ranged from 375 to 600 mg every eight hours, and that of oral acyclovir ranged from 200 to 800 mg five times a day. The average duration of treatment with intravenous or oral acyclovir was 10.8 days among the vaccinated patients and 9.8 days among those who were not vaccinated; one patient in each group was treated for more than 21 days. Twelve vaccinated patients and 14 unvaccinated patients died within 12 months after transplantation. Survival in the two groups was similar at a median follow-up time of 24.2 months (range, 0.9 to 56.0) (Figure 1Figure 1
Probability of Overall Survival among Recipients of Autologous Hematopoietic-Cell Transplants Who Were Randomly Assigned to Receive Inactivated Varicella Vaccine or No Vaccine.).Tolerability of the Vaccine
All the patients in the vaccine group received the first dose of vaccine before the scheduled transplantation (mean, 13 days before transplantation; range, 2 to 34). Of the 53 patients in the vaccine group who underwent transplantation, 45 received three doses of the vaccine and 43 received four doses. Two patients in this group withdrew at 30 days for unexplained reasons, and 1 withdrew because of disease progression; 10 other patients in this group with disease progression continued to participate in the study. Twelve patients had local symptoms at the site of vaccination on at least one occasion, and one patient reported headache. Adverse reactions occurred with 20 of 198 doses of the vaccine (10 percent); local pain, induration, and erythema were the most common reactions.
Development of Zoster
Zoster was diagnosed within 12 months after transplantation in 7 of 53 patients in the vaccine group (13 percent) and in 19 of 58 patients in the control group (33 percent) (P=0.01) (Table 1 and Figure 2Figure 2
Probability of Zoster among Recipients of Autologous Hematopoietic-Cell Transplants Who Were Randomly Assigned to Receive Inactivated Varicella Vaccine or No Vaccine.). The difference remained significant when two patients in the control group in whom zoster developed before transplantation were excluded (leaving 17 patients with zoster of 56 [30 percent]) (P=0.02). The median interval between transplantation and the diagnosis of zoster was 92 days (mean, 129) in the vaccine group and 130 days (mean, 166) in the control group (P=0.41 for the comparison of the median intervals). One vaccinated patient and two unvaccinated patients had a relapse of disease before zoster developed. All the patients, regardless of study group, in whom zoster developed received antiviral treatment for zoster. The severity of zoster did not differ between the two groups.Immunity against Varicella–Zoster Virus
In vitro CD4 T-cell proliferation in response to varicella–zoster virus appeared earlier in peripheral-blood specimens from the vaccinated patients than it did in specimens from the unvaccinated patients. Since the proliferative response increased after an episode of zoster, any evaluations after such episodes were excluded from the analysis. Before transplantation, the mean (±SE) stimulation index was similar in the two groups (8.2±1.65 in the vaccine group and 9.9±2.32 in the control group, P=0.39), and responses remained similar and low 30 days after transplantation. By 90 days, the mean stimulation index was 15.7±3.47 in the vaccine group and 8.0±1.63 in the control group (P=0.04); the difference between the groups was significant 120 days (P<0.001) and 6 months (P=0.004) after transplantation (Figure 3Figure 3
CD4 T-Cell Proliferation in Response to Varicella–Zoster Virus Antigen among Recipients of Hematopoietic-Cell Transplants Who Were Randomly Assigned to Receive Inactivated Varicella Vaccine or No Vaccine.). The patients in the vaccine group had significantly higher mean stimulation indexes at 6 months (P=0.01) and at 12 months (P<0.001) than they did before transplantation; among the patients in the control group the difference was not significant (P=0.30 for the comparison between pretransplantation values and the values at 6 months and P=0.46 for the comparison between pretransplantation values and the values at 12 months). At 12 months, the mean stimulation index was higher in the vaccine group than in the control group (42.8±8.30 vs. 21.3±5.91, P=0.02).Immunity against varicella–zoster virus was evaluated by testing for intracellular cytokines in 19 patients in each group six months after transplantation. These two subgroups were balanced with respect to mean age (43 years [range, 21 to 58] in those who were vaccinated and 40 years [range, 19 to 59] in those who were not vaccinated), number of men (13 and 13), and diagnosis of Hodgkin's disease (5 and 6, respectively) and non-Hodgkin's lymphoma (14 and 13, respectively); all the patients survived for more than 12 months after transplantation. The proportion of CD4 T cells that produced TNF-α was 0.50±0.12 percent in the subgroup of vaccinated patients and 0.19±0.07 percent in the subgroup of unvaccinated patients (P=0.03) (Figure 4Figure 4
Expression of Interferon-γ and Tumor Necrosis Factor α (TNF-α) in CD4 T Cells Incubated with Varicella–Zoster Virus.). The proportions of interferon-γ–positive CD4 T cells were 0.33±0.11 percent and 0.11±0.05 percent, respectively (P=0.07).Titers of varicella–zoster virus IgG antibody before transplantation ranged from 1:256 to 1:16,384 on testing by enzyme-linked immunosorbent assay and did not differ between the two groups, according to the unpaired t-test. Six months after transplantation, the IgG titers had increased by a factor of four in 6 of the 106 patients who had not had zoster (3 in the vaccine group and 3 in the control group), and they had decreased by a factor of four in 7 patients (4 in the vaccine group and 3 in the control group); the titers did not change in the remaining 93 patients.
Risk of Zoster and Rate of Varicella–Zoster Virus–Specific CD4 T-Cell Proliferation
Cox proportional-hazards analysis with time-dependent covariate analysis was used to assess the relative risk of zoster as predicted by the stimulation index. Both vaccinated and unvaccinated patients were included in this analysis. Before the development of zoster, the stimulation indexes in patients in whom zoster subsequently developed were significantly different from the stimulation indexes in patients in whom zoster never developed and who were tested at the same interval after transplantation (P=0.008; relative risk of zoster, 0.81; 95 percent confidence interval, 0.69 to 0.95). Patients who had a stimulation index of 1.6 or above had a significantly lower risk of zoster than those with a stimulation index below 1.6 (P=0.006; relative risk of zoster, 0.32; 95 percent confidence interval, 0.14 to 0.70). A patient who had a stimulation index above 1.6 had a 68 percent lower probability of subsequently having zoster than a patient with a stimulation index below 1.6 (95 percent confidence interval, 0.32 to 1.0). If the stimulation index was greater than or equal to 3.0, the risk was 76 percent lower than it was with an index below 1.6; if the index was greater than or equal to 4.0, the risk was 83 percent lower; and if the index was greater than or equal to 5.0, the risk was 93 percent lower.
Immune Reconstitution
The mean stimulation index before the onset of zoster was 4.9±1.18 in the 7 patients in the vaccine group in whom zoster subsequently developed and 2.2±0.4 in 19 such patients in the control group (P=0.01). After the resolution of zoster, the stimulation index increased to 55.0±20.76 and 28.1±6.68 (in 18 patients in the control group), respectively (P=0.34).
Discussion
Reactivation of varicella–zoster virus is a persistent source of illness in recipients of hematopoietic-cell transplants, despite antiviral therapy.2,12-15,34,35 We found that the administration of an investigational inactivated varicella vaccine, in a regimen in which one dose was given before transplantation and three doses were given after transplantation, offered substantial protection from zoster among patients with lymphoma who received an autologous transplant.
The risk of zoster is high among patients with impaired cell-mediated immunity against varicella–zoster virus.8-16,31,34,35 The relation that we observed between vaccine-induced reconstitution of T-cell immunity against varicella–zoster virus and a decreased incidence of zoster shows that cellular immunity modulates the capacity of latent herpesviruses to reactivate and cause disease. The proliferation of CD4 T cells specific for varicella–zoster virus was detected earlier in patients who were reexposed to varicella–zoster virus antigens by vaccination just before autologous transplantation; this finding suggests that mature, antigen-specific T cells may persist during the preparatory regimen.36
Restoration of immunity against varicella–zoster virus was measured with the use of a simple in vitro assay of CD4 T-cell proliferation. Our evaluation of patients who were being monitored for zoster showed that a high stimulation index, as determined by this assay, was an immunologic correlate of protection. A stimulation index above 5.0 was highly predictive of protection from zoster. In healthy adults who have immunity to varicella–zoster virus, the stimulation index ranges from 5.0 to more than 20.0.31 The relation between a high stimulation index and a reduced risk of zoster may reflect the contribution of varicella–zoster virus–specific CD4 T cells to the control of viral replication, since these cells make interferon-γ and other cytokines and are cytotoxic to cells infected with the virus.14,17,31,32 Protection against zoster after immunization with inactivated varicella vaccine may be due to the early restoration of antiviral CD4 T cells to levels found in populations at low risk for zoster.32,37-40 Reconstitution of varicella–zoster virus–specific CD4 T cells by vaccination may provide helper functions necessary to expand varicella–zoster virus–specific CD8 T-cell populations that are essential to preserving the latency of the virus.14,31 In studies of immunity to human cytomegalovirus, another herpesvirus, the adoptive transfer of cytomegalovirus-specific CD8 T cells to patients who received bone marrow transplants resulted in effective antiviral immunity if the patient had anti-cytomegalovirus CD4 T cells.41,42
Inactivated vaccines containing multiple viral proteins, like the vaccine we tested, or those formulated with viral protein subunits may be useful for accelerating the recovery of cellular immunity to other herpesviruses, especially human cytomegalovirus; infection with cytomegalovirus is more difficult to diagnose and treat in immunocompromised patients than infection with varicella–zoster virus.43 The persistence of T-cell immunity against varicella–zoster virus for 12 months after transplantation and the higher stimulation index in vaccinated patients 12 months after transplantation than before transplantation suggest robust reconstitution, as has been observed in such patients with some bacterial vaccines.44-46 Although the use of a varicella vaccine after allogeneic hematopoietic-cell transplantation did not reduce the incidence of zoster,22 immunization before transplantation or immunization of the donor might enhance the effectiveness of the vaccine.45 A regimen of vaccination both before and after transplantation might be particularly effective for patients with herpesvirus infections, because antiviral immunity may be stimulated further by subclinical reactivation of the latent virus. The use of fewer than three doses after transplantation might be sufficient, since the proliferation of T cells specific for varicella–zoster virus was significantly enhanced at 90 days after transplantation, after three doses of inactivated varicella vaccine had been given, as compared with that in the control group. The principle of vaccination before transplantation to stimulate antigen-specific memory T cells in numbers sufficient to allow some T cells to survive the preparatory regimen, coupled with subsequent post-transplantation doses, should be generally applicable.
Supported by a grant (PO1-CA49605, to Dr. Blume) from the National Cancer Institute and by postdoctoral fellowships from the Japan Herpesvirus Infection Forum (to Drs. Hata and Asanuma); the inactivated varicella vaccine was supplied by Merck.
Dr. Arvin has received research support from Merck for studies of live attenuated varicella vaccine and received an honorarium for an educational program; currently, she has no research contracts or personal financial relationship with the company.
We are indebted to the patients for their participation; to Robert Negrin, M.D., and our colleagues at the Stanford Hematopoietic Cell Transplantation Program; to Byron W. Brown, Ph.D., Department of Health Research and Policy, Stanford University, for statistical contributions; and to the data and safety monitoring board for guidance.
Source Information
From the Departments of Pediatrics (A.H., H.A., M.R., M.S., A.M.A.), Health Research and Policy (R.M.W.), and Medicine (K.B.), Stanford University School of Medicine, Stanford, Calif.
Address reprint requests to Dr. Arvin at the Department of Pediatrics, Stanford University School of Medicine, 300 Pasteur Dr., Rm. G312, Stanford, CA 94305-5208.
- References
References
1
Arvin AM . Varicella-zoster virus: pathogenesis, immunity, and clinical management in hematopoietic cell transplant recipients. Biol Blood Marrow Transplant 2000;6:219-230
CrossRef | Web of Science | Medline2
Whitley RJ. Varicella-zoster virus infection. In: Galasso GJ, Whitley RJ, Merigan TC, eds. Antiviral agents and viral diseases of man. 3rd ed. New York: Raven Press, 1990:235-63.
3
Silverstein S, Straus SE. Pathogenesis of latency and reactivation. In: Arvin AM, Gershon AA, eds. Varicella-zoster virus: virology and clinical practice. Cambridge, England: Cambridge University Press, 2000:123-41.
4
Lungu O ,Annunziato PW ,Gershon A , et al. Reactivated and latent varicella-zoster virus in human dorsal root ganglia. Proc Natl Acad Sci U S A 1995;92:10980-10984
CrossRef | Web of Science | Medline5
Mahalingam R ,Wellish M ,Cohrs R , et al. Expression of protein encoded by varicella-zoster virus open reading frame 63 in latently infected human ganglionic neurons. Proc Natl Acad Sci U S A 1996;93:2122-2124
CrossRef | Web of Science | Medline6
Kennedy PG ,Grinfeld E ,Gow JW . Latent varicella-zoster virus is located predominantly in neurons in human trigeminal ganglia. Proc Natl Acad Sci U S A 1998;95:4658-4662
CrossRef | Web of Science | Medline7
Pevenstein SR ,Williams RK ,McChesney D ,Mont EK ,Smialek JE ,Straus SE . Quantitation of latent varicella-zoster virus and herpes simplex virus genomes in human trigeminal ganglia. J Virol 1999;73:10514-10518
Web of Science | Medline8
Arvin AM. Varicella zoster virus infections. In: Thomas ED, Blume KG, Forman SJ, eds. Hematopoietic cell transplantation. 2nd ed. Malden, Mass.: Blackwell Science, 1999:591-606.
9
Schuchter LM ,Wingard JR ,Piantadosi S ,Burns WH ,Santos GW ,Saral R . Herpes zoster infection after autologous bone marrow transplantation. Blood 1989;74:1424-1427
Web of Science | Medline10
Holland HK ,Wingard JR ,Saral R . Herpesvirus and enteric viral infections in bone marrow transplantation: clinical presentations, pathogenesis, and therapeutic strategies. Cancer Invest 1990;8:509-521
CrossRef | Web of Science | Medline11
Wacker P ,Hartmann O ,Benhamou E ,Salloum E ,Lemerle J . Varicella-zoster virus infections after autologous bone marrow transplantation in children. Bone Marrow Transplant 1989;4:191-194
Web of Science | Medline12
Zaia JA . Viral infections associated with bone marrow transplantation. Hematol Oncol Clin North Am 1990;4:603-623
Web of Science | Medline13
Han CS ,Miller W ,Haake R ,Weisdorf D . Varicella zoster infection after bone marrow transplantation: incidence, risk factors and complications. Bone Marrow Transplant 1994;13:277-283
Web of Science | Medline14
Wilson A ,Sharp M ,Koropchak CM ,Ting SF ,Arvin AM . Subclinical varicella-zoster virus viremia, herpes zoster, and T-lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation. J Infect Dis 1992;165:119-126
CrossRef | Web of Science | Medline15
Koc Y ,Miller KB ,Schenkein DP , et al. Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome. Biol Blood Marrow Transplant 2000;6:44-49
CrossRef | Web of Science | Medline16
Meyers JD ,Flournoy N ,Thomas ED . Cell-mediated immunity to varicella-zoster virus after allogeneic bone marrow transplant. J Infect Dis 1980;141:479-487
CrossRef | Web of Science | Medline17
Zhang Y ,Cosyns M ,Levin MJ ,Hayward AR . Cytokine production in varicella zoster virus-stimulating limiting dilution lymphocyte cultures. Clin Exp Immunol 1994;98:128-133
CrossRef | Web of Science | Medline18
Webster A ,Grint P ,Brenner MK ,Prentice HG ,Griffiths PD . Titration of IgG antibodies against varicella zoster virus before bone marrow transplantation is not predictive of future zoster. J Med Virol 1989;27:117-119
CrossRef | Web of Science | Medline19
Gershon AA . Live-attenuated varicella vaccine. Infect Dis Clin North Am 2001;15:65-81
CrossRef | Web of Science | Medline20
Levin MJ . Use of varicella vaccines to prevent herpes zoster in older individuals. Arch Virol Suppl 2001;17:151-160
Medline21
Sperber SJ ,Smith BV ,Hayden FG . Serologic response and reactogenicity to booster immunization of healthy seropositive adults with live or inactivated varicella vaccine. Antiviral Res 1992;17:213-222
CrossRef | Web of Science | Medline22
Redman RL ,Nader S ,Zerboni L , et al. Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine. J Infect Dis 1997;176:578-585
CrossRef | Web of Science | Medline23
Wimperis JZ ,Brenner MK ,Prentice HG , et al. Transfer of a functioning humoral immune system in transplantation of T-lymphocyte-depleted bone marrow. Lancet 1986;1:339-343
CrossRef | Web of Science | Medline24
Saxon A. Reconstitution of specific immunity following bone marrow transplantation. In: Gale RP, Champlin R, eds. Progress in bone marrow transplantation. New York: Alan R. Liss, 1987:623-33.
25
Ambrosino DM ,Molrine DC . Critical appraisal of immunization strategies for prevention of infection in the compromised host. Hematol Oncol Clin North Am 1993;7:1027-1050
Web of Science | Medline26
Stuart MJ ,Chao NS ,Horning SJ , et al. Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease. Biol Blood Marrow Transplant 2001;7:552-560
CrossRef | Web of Science | Medline27
Horning SJ ,Chao NJ ,Negrin RS , et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood 1997;89:801-813
Web of Science | Medline28
Stockerl-Goldstein KE ,Horning SJ ,Negrin RS , et al. Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 1996;2:76-85
Medline29
Johnston LJ ,Stockerl-Goldstein KE ,Hu WW , et al. Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2000;6:555-562
CrossRef | Web of Science | Medline30
Negrin RS ,Kusnierz-Glaz CR ,Still BJ , et al. Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma. Blood 1995;85:3334-3341
Web of Science | Medline31
Arvin AM. Varicella-zoster virus. In: Ahmed R, Chen ISY, eds. Persistent viral infections. Chichester, England: John Wiley, 1999:183-208.
32
Asanuma H ,Sharp M ,Maecker HT ,Maino VC ,Arvin AM . Frequencies of memory T cells specific for varicella-zoster virus, herpes simplex virus, and cytomegalovirus determined by intracellular detection of cytokine expression. J Infect Dis 2000;181:859-866
CrossRef | Web of Science | Medline33
Estimating Cox regression models with PROC PHREG. In: Allison PD. Survival analysis using the SAS system: a practical guide. Cary, N.C.: SAS Institute, 1995:111-84.
34
Wingard JR . Management of infectious complications of bone marrow transplantation. Oncology (Huntingt) 1990;4:69-75
Medline35
Ljungman P ,Lonnqvist B ,Ringden O ,Skinhoj P ,Gahrton G . A randomized trial of oral versus intravenous acyclovir for treatment of herpes zoster in bone marrow transplant recipients. Bone Marrow Transplant 1989;4:613-615
Web of Science | Medline36
de Gast GC ,Verdonck LF ,Middeldorp JM , et al. Recovery of T cell subsets after autologous bone marrow transplantation is mainly due to proliferation of mature T cells in the graft. Blood 1985;66:428-431
Web of Science | Medline37
Altman JD ,Moss P ,Goulder PJ , et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996;274:94-96[Erratum, Science 1998;280:1821.]
CrossRef | Web of Science | Medline38
Ahmed R ,Gray D . Immunological memory and protective immunity: understanding their relation. Science 1996;272:54-60
CrossRef | Web of Science | Medline39
Doherty PC . The numbers game for virus-specific CD8+ T cells. Science 1998;280:227-227
CrossRef | Web of Science | Medline40
Smith JG ,Liu X ,Kaufhold RM ,Clair J ,Caulfield MJ . Development and validation of a gamma interferon ELISPOT assay for quantitation of cellular immune responses to varicella-zoster virus. Clin Diagn Lab Immunol 2001;8:871-879
Medline41
Walter EA ,Greenberg PD ,Gilbert MJ , et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995;333:1038-1044
Full Text | Web of Science | Medline42
Greenberg PD ,Riddell SR . Deficient cellular immunity -- finding and fixing the defects. Science 1999;285:546-551
CrossRef | Web of Science | Medline43
Zaia JA ,Forman SJ . Cytomegalovirus infection in the bone marrow transplant recipient. Infect Dis Clin North Am 1995;9:879-900
Web of Science | Medline44
Molrine DC ,Guinan EC ,Antin JH , et al. Donor immunization with Haemophilus influenzae type b (HIB)-conjugate vaccine in allogeneic bone marrow transplantation. Blood 1996;87:3012-3018
Web of Science | Medline45
Ljungman P ,Wiklund-Hammarsten M ,Duraj V , et al. Response to tetanus toxoid immunization after allogeneic bone marrow transplantation. J Infect Dis 1990;162:496-500
CrossRef | Web of Science | Medline46
Guinan EC ,Molrine DC ,Antin JH , et al. Polysaccharide conjugate vaccine responses in bone marrow transplant patients. Transplantation 1994;57:677-684
CrossRef | Web of Science | Medline
- Citing Articles (89)
Citing Articles
1
Najoua Dendouga, Michel Fochesato, Laurence Lockman, Sally Mossman, Sandra L. Giannini. (2012) Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice. Vaccine
CrossRef2
Naruhito Otani, Kiyofumi Yamanishi, Yoshiko Sakaguchi, Yasutomo Imai, Masayuki Shima, Toshiomi Okuno. (2012) Varicella-zoster virus-specific cell-mediated immunity in subjects with herpes zoster. Journal of Immunological Methods
CrossRef3
Josh Levitsky, Natasha Walzer. 2011. Hepatobiliary Complications of Hematopoietic Cell Transplantation. , 255-270.
CrossRef4
Gitte Vrelits Sørensen, Steen Rosthøj, Morten Würtz, Tore Kristian Danielsen, Henrik Schrøder. (2011) The epidemiology of herpes zoster in 226 children with acute lymphoblastic leukemia. Pediatric Blood & Cancer 57:6, 993-997
CrossRef5
Nathalie De Castro, Maryvonnick Carmagnat, Solen Kernéis, Catherine Scieux, Claire Rabian, Jean-Michel Molina. (2011) Varicella-Zoster Virus-Specific Cell-Mediated Immune Reponses in HIV-Infected Adults. AIDS Research and Human Retroviruses 27:10, 1089-1097
CrossRef6
Daniel KL Cheuk, Virginia Wong, Wen Xiong Chen, Daniel KL Cheuk. 2011. Acupuncture for autism spectrum disorders (ASD). .
CrossRef7
D. Gilden, R. Mahalingam, M. A. Nagel, S. Pugazhenthi, R. J. Cohrs. (2011) Review: The neurobiology of varicella zoster virus infection. Neuropathology and Applied Neurobiology 37:5, 441-463
CrossRef8
Shih Hann Su, Valérie Martel-Laferrière, Annie-Claude Labbé, David R. Snydman, David Kent, Michel Laverdière, Claire Béliveau, Tanya Logvinenko, Sandra Cohen, Silvy Lachance, Thomas Kiss, Jean Roy. (2011) High Incidence of Herpes Zoster in Nonmyeloablative Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 17:7, 1012-1017
CrossRef9
Simone Thomas, Wolfgang Herr. (2011) Natural and adoptive T-cell immunity against herpes family viruses after allogeneic hematopoietic stem cell transplantation. Immunotherapy 3:6, 771-788
CrossRef10
D. Gilden. (2011) Efficacy of live zoster vaccine in preventing zoster and postherpetic neuralgia. Journal of Internal Medicine 269:5, 496-506
CrossRef11
Ning Chen, Qifu Li, Yun Zhang, Muke Zhou, Dong Zhou, Li He, Li He. 2011. Vaccination for preventing postherpetic neuralgia. .
CrossRef12
Daniel KL Cheuk, Alan KS Chiang, Tsz Leung Lee, Godfrey CF Chan, Shau Yin Ha, Daniel KL Cheuk. 2011. Vaccines for prophylaxis of viral infections in patients with hematological malignancies. .
CrossRef13
Trudy N Small, Morton J Cowan. (2011) Immunization of hematopoietic stem cell transplant recipients against vaccine-preventable diseases. Expert Review of Clinical Immunology 7:2, 193-203
CrossRef14
S.A. Pergam, C.W. Forsberg, M.J. Boeckh, C. Maynard, A.P. Limaye, A. Wald, N.L. Smith, B.A. Young. (2011) Herpes zoster incidence in a multicenter cohort of solid organ transplant recipients. Transplant Infectious Disease 13:1, 15-23
CrossRef15
Kevin Shiley, Emily Blumberg. (2011) Herpes Viruses in Transplant Recipients: HSV, VZV, Human Herpes Viruses, and EBV. Hematology/Oncology Clinics of North America 25:1, 171-191
CrossRef16
Brian T. Fisher, Sarah Alexander, Christopher C. Dvorak, Theoklis E. Zaoutis, Danielle M. Zerr, Lillian Sung. (2011) Epidemiology and potential preventative measures for viral infections in children with malignancy and those undergoing hematopoietic cell transplantation. Pediatric Blood & Cancern/a-n/a
CrossRef17
K. Oshima, T. Takahashi, T. Mori, T. Matsuyama, K. Usuki, Y. Asano-Mori, F. Nakahara, S. Okamoto, M. Kurokawa, Y. Kanda. (2010) One-year low-dose valacyclovir as prophylaxis for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation. A prospective study of the Japan Hematology and Oncology Clinical Study Group. Transplant Infectious Disease 12:5, 421-427
CrossRef18
Kevin Shiley, Emily Blumberg. (2010) Herpes Viruses in Transplant Recipients: HSV, VZV, Human Herpes Viruses, and EBV. Infectious Disease Clinics of North America 24:2, 373-393
CrossRef19
Anne A. Gershon, Michael D. Gershon, Judith Breuer, Myron J. Levin, Anne Louise Oaklander, Paul D. Griffiths. (2010) Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. Journal of Clinical Virology 48, S2-S7
CrossRef20
Joel V Chua, Wilbur H Chen. (2010) Herpes zoster vaccine for the elderly: boosting immunity. Aging Health 6:2, 169-176
CrossRef21
C. N. Kotton, P. L. Hibberd, . (2009) Travel Medicine and the Solid Organ Transplant Recipient. American Journal of Transplantation 9, S273-S281
CrossRef22
S. A. Pergam, A. P. Limaye, . (2009) Varicella Zoster Virus (VZV) in Solid Organ Transplant Recipients. American Journal of Transplantation 9, S108-S115
CrossRef23
Naruhito Otani, Koichi Baba, Toshiomi Okuno. (2009) Interferon-γ release assay: A simple method for detection of varicella-zoster virus-specific cell-mediated immunity. Journal of Immunological Methods 351:1-2, 71-74
CrossRef24
(2009) References. Bone Marrow Transplantation 44:8, 537-557
CrossRef25
Marcie Tomblyn, Tom Chiller, Hermann Einsele, Ronald Gress, Kent Sepkowitz, Jan Storek, John R. Wingard, Jo-Anne H. Young, Michael A. Boeckh. (2009) Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective. Biology of Blood and Marrow Transplantation 15:10, 1143-1238
CrossRef26
Joshua Brody, Ronald Levy. (2009) Lymphoma immunotherapy: vaccines, adoptive cell transfer and immunotransplant. Immunotherapy 1:5, 809-824
CrossRef27
Wolfgang Herr, Bodo Plachter. (2009) Cytomegalovirus and varicella–zoster virus vaccines in hematopoietic stem cell transplantation. Expert Review of Vaccines 8:8, 999-1021
CrossRef28
Masahiro Onozawa, Satoshi Hashino, Yoshifumi Haseyama, Yasuo Hirayama, Susumu Iizuka, Tadao Ishida, Makoto Kaneda, Hajime Kobayashi, Ryoji Kobayashi, Kyuhei Koda, Mitsutoshi Kurosawa, Nobuo Masauji, Takuya Matsunaga, Akio Mori, Masaya Mukai, Mitsufumi Nishio, Satoshi Noto, Shuichi Ota, Hajime Sakai, Nobuhiro Suzuki, Tohru Takahashi, Junji Tanaka, Yoshihiro Torimoto, Makoto Yoshida, Takashi Fukuhara. (2009) Incidence and Risk of Postherpetic Neuralgia after Varicella Zoster Virus Infection in Hematopoietic Cell Transplantation Recipients: Hokkaido Hematology Study Group. Biology of Blood and Marrow Transplantation 15:6, 724-729
CrossRef29
J Styczynski, P Reusser, H Einsele, R de la Camara, C Cordonnier, K N Ward, P Ljungman, D Engelhard. (2009) Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplantation 43:10, 757-770
CrossRef30
Rosella Creed, Anita Satyaprakash, Parisa Ravanfar. (2009) Varicella zoster vaccines. Dermatologic Therapy 22:2, 143-149
CrossRef31
Leonardo Fuks, David Shitrit, Benjamin D. Fox, Anat Amital, Yael Raviv, Ilana Bakal, Mordechai R. Kramer. (2009) Herpes Zoster After Lung Transplantation: Incidence, Timing, and Outcome. The Annals of Thoracic Surgery 87:2, 423-426
CrossRef32
Eva Distler, Elke Schnürer, Eva Wagner, Charis von Auer, Bodo Plachter, Daniela Wehler, Christoph Huber, Karin Kolbe, Ralf Georg Meyer, Wolfgang Herr. (2008) Recovery of Varicella-Zoster Virus–Specific T Cell Immunity after T Cell–Depleted Allogeneic Transplantation Requires Symptomatic Virus Reactivation. Biology of Blood and Marrow Transplantation 14:12, 1417-1424
CrossRef33
Kay Sadaoka, Shigefumi Okamoto, Yasuyuki Gomi, Takeshi Tanimoto, Toyokazu Ishikawa, Tetsushi Yoshikawa, Yoshizo Asano, Koichi Yamanishi, Yasuko Mori. (2008) Measurement of Varicella‐Zoster Virus (VZV)–Specific Cell‐Mediated Immunity: Comparison between VZV Skin Test and Interferon‐γ Enzyme‐Linked Immunospot Assay. The Journal of Infectious Diseases 198:9, 1327-1333
CrossRef34
Camille Nelson Kotton. (2008) Skin and soft tissue infections in the transplant population. Current Infectious Disease Reports 10:5, 387-393
CrossRef35
Kristel Vandenbosch, Philippe Ovetchkine, Martin A. Champagne, Elie Haddad, Lubomir Alexandrov, Michel Duval. (2008) Varicella-Zoster Virus Disease Is More Frequent after Cord Blood Than after Bone Marrow Transplantation. Biology of Blood and Marrow Transplantation 14:8, 867-871
CrossRef36
Marissa B Wilck, Lindsey R Baden. (2008) Vaccination after stem cell transplant: a review of recent developments and implications for current practice. Current Opinion in Infectious Diseases 21:4, 399-408
CrossRef37
Kristine Macartney, Peter McIntyre, Kristine Macartney. 2008. Vaccines for post-exposure prophylaxis against varicella (chickenpox) in children and adults. .
CrossRef38
Camille Nelson Kotton. (2008) Vaccination and immunization against travel-related diseases in immunocompromised hosts. Expert Review of Vaccines 7:5, 663-672
CrossRef39
Yuki Asano-Mori, Yoshinobu Kanda, Kumi Oshima, Shinichi Kako, Akihito Shinohara, Hideki Nakasone, Hiroyuki Sato, Takuro Watanabe, Noriko Hosoya, Koji Izutsu, Takashi Asai, Akira Hangaishi, Toru Motokura, Shigeru Chiba, Mineo Kurokawa. (2008) Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. American Journal of Hematology 83:6, 472-476
CrossRef40
T. Glück, U. Müller‐Ladner. (2008) Vaccines: Vaccination in Patients with Chronic Rheumatic or Autoimmune Diseases. Clinical Infectious Diseases 46:9, 1459-1465
CrossRef41
M. J. Levin, M. N. Oxman, J. H. Zhang, G. R. Johnson, H. Stanley, A. R. Hayward, M. J. Caulfield, M. R. Irwin, J. G. Smith, J. Clair, I. S. F. Chan, H. Williams, R. Harbecke, R. Marchese, S. E. Straus, A. Gershon, A. Weinberg, . (2008) Varicella‐Zoster Virus–Specific Immune Responses in Elderly Recipients of a Herpes Zoster Vaccine. The Journal of Infectious Diseases 197:6, 825-835
CrossRef42
Myron J. Levin. (2008) Varicella Vaccination of Immunocompromised Children. The Journal of Infectious Diseases 197:s2, S200-S206
CrossRef43
Christine Orlova Urman, Alice B. Gottlieb. (2008) New viral vaccines for dermatologic disease. Journal of the American Academy of Dermatology 58:3, 361-370
CrossRef44
Michael N. Oxman, Myron J. Levin, . (2008) Vaccination against Herpes Zoster and Postherpetic Neuralgia. The Journal of Infectious Diseases 197:s2, S228-S236
CrossRef45
Jeffrey I. Cohen. (2008) Strategies for Herpes Zoster Vaccination of Immunocompromised Patients. The Journal of Infectious Diseases 197:s2, S237-S241
CrossRef46
Oriol Manuel, Deepali Kumar, Lianne G. Singer, Isabel Cobos, Atul Humar. (2008) Incidence and Clinical Characteristics of Herpes Zoster After Lung Transplantation. The Journal of Heart and Lung Transplantation 27:1, 11-16
CrossRef47
Julio Sotelo. (2007) On the viral hypothesis of multiple sclerosis: Participation of varicella-zoster virus. Journal of the Neurological Sciences 262:1-2, 113-116
CrossRef48
James L.M. Ferrara, Claudio Anasetti, Edward Stadtmauer, Joseph Antin, John Wingard, Stephanie Lee, John Levine, Kirk Schultz, Frederick Appelbaum, Robert Negrin, Sergio Giralt, Christopher Bredeson, Helen Heslop, Mary Horowitz. (2007) Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2007. Biology of Blood and Marrow Transplantation 13:11, 1268-1285
CrossRef49
V. Erard, K. A. Guthrie, C. Varley, J. Heugel, A. Wald, M. E. D. Flowers, L. Corey, M. Boeckh. (2007) One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood 110:8, 3071-3077
CrossRef50
I. M. Svane, K. Nikolajsen, H. E. Johnsen. (2007) Antigen-Specific T-Cell Immunity in Multiple Myeloma Patients is Restored Following High-Dose Therapy: Implications for Timing of Vaccination. Scandinavian Journal of Immunology 66:4, 465-475
CrossRef51
Camille Nelson Kotton. (2007) Nailing down the shingles in IBD. Inflammatory Bowel Diseases 13:9, 1178-1179
CrossRef52
J. N. Kochenderfer, J. L. Simpson, C. D. Chien, R. E. Gress. (2007) Vaccination regimens incorporating CpG-containing oligodeoxynucleotides and IL-2 generate antigen-specific antitumor immunity from T-cell populations undergoing homeostatic peripheral expansion after BMT. Blood 110:1, 450-460
CrossRef53
M.W. McKendrick, J. Lau, S. Alston, J. Bremner. (2007) VZV infection in pregnancy: A retrospective review over 5 years in Sheffield and discussion on the potential utilisation of varicella vaccine in prevention. Journal of Infection 55:1, 64-67
CrossRef54
A Y H Leung, H C H Chow, J S Y Kwok, C K H Lui, V C C Cheng, K-Y Yuen, A K W Lie, R Liang. (2007) Safety of vaccinating sibling donors with live-attenuated varicella zoster vaccine before hematopoietic stem cell transplantation. Bone Marrow Transplantation 39:11, 661-665
CrossRef55
Daniel KL Cheuk, Alan KS Chiang, Tsz Leung Lee, Godfrey CF Chan, Shau Yin Ha, Yu Lung Lau, Daniel KL Cheuk. 2007. Vaccines for prophylaxis of viral infections in patients with hematological malignancies. .
CrossRef56
Julio Sotelo, Graciela Ordoñez, Benjamin Pineda. (2007) Varicella-zoster virus at relapses of multiple sclerosis. Journal of Neurology 254:4, 493-500
CrossRef57
G. G. Miller, J. S. Dummer. (2007) Herpes Simplex and Varicella Zoster Viruses: Forgotten but Not Gone. American Journal of Transplantation 7:4, 741-747
CrossRef58
Lawrence A. Hunt. 2006. Cytomegalovirus and Varicella-Zoster Virus Vaccines. .
CrossRef59
Pamela P. W. Lee, Tze-Leung Lee, Marco Hok-Kung Ho, Wilfred H. S. Wong, Yu-Lung Lau. (2006) Herpes Zoster in Juvenile-Onset Systemic Lupus Erythematosus. The Pediatric Infectious Disease Journal 25:8, 728-732
CrossRef60
A. Weinberg, S.P. Horslen, S.S. Kaufman, R. Jesser, A. DeVoll-Zabrocki, B.L. Fleckten, S. Kochanowicz, K.R. Seipel, M.J. Levin. (2006) Safety and Immunogenicity of Varicella-Zoster Virus Vaccine in Pediatric Liver and Intestine Transplant Recipients. American Journal of Transplantation 6:3, 565-568
CrossRef61
A P Rapoport. (2006) Immunity for tumors and microbes after autotransplantation: if you build it, they will (not) come. Bone Marrow Transplantation 37:3, 239-247
CrossRef62
Mara Dinits-Pensy, Graeme N. Forrest, Alan S. Cross, Michael K. Hise. (2005) The Use of Vaccines in Adult Patients With Renal Disease. American Journal of Kidney Diseases 46:6, 997-1011
CrossRef63
Israel Steiner. (2005) Can vaccinating older adults against varicella zoster virus prevent herpes zoster and postherpetic neuralgia?. Nature Clinical Practice Neurology 1:1, 18-19
CrossRef64
J N Berman, M Wang, W Berry, D S Neuberg, E C Guinan. (2005) Herpes zoster infection in the post-hematopoietic stem cell transplant pediatric population may be preceded by transaminitis: an institutional experience. Bone Marrow Transplantation
CrossRef65
Andrew L. Campbell, Betsy C. Herold. (2005) Immunization of pediatric solid-organ transplantation candidates: Immunizations in transplant candidates. Pediatric Transplantation 9:5, 652-661
CrossRef66
Bjorn Hackanson, Robert Zeiser, Thorsten A Bley, Georgios Pantazis, Daniela Huzly, Hartmut Bertz, Jurgen Finke. (2005) Fatal varicella zoster virus encephalitis in two patients following allogeneic hematopoietic stem cell transplantation. Clinical Transplantation 19:4, 566-570
CrossRef67
P D Griffiths. (2005) A shot in the arm for immunotherapy. Reviews in Medical Virology 15:4, 215-217
CrossRef68
Arvin, Ann, . (2005) Aging, Immunity, and the Varicella–Zoster Virus. New England Journal of Medicine 352:22, 2266-2267
Full Text69
Oxman, M.N., Levin, M.J., Johnson, G.R., Schmader, K.E., Straus, S.E., Gelb, L.D., Arbeit, R.D., Simberkoff, M.S., Gershon, A.A., Davis, L.E., Weinberg, A., Boardman, K.D., Williams, H.M., Zhang, J. Hongyuan, Peduzzi, P.N., Beisel, C.E., Morrison, V.A., Guatelli, J.C., Brooks, P.A., Kauffman, C.A., Pachucki, C.T., Neuzil, K.M., Betts, R.F., Wright, P.F., Griffin, M.R., Brunell, P., Soto, N.E., Marques, A.R., Keay, S.K., Goodman, R.P., Cotton, D.J., Gnann, J.W. Jr., Loutit, J., Holodniy, M., Keitel, W.A., Crawford, G.E., Yeh, S.-S., Lobo, Z., Toney, J.F., Greenberg, R.N., Keller, P.M., Harbecke, R., Hayward, A.R., Irwin, M.R., Kyriakides, T.C., Chan, C.Y., Chan, I.S.F., Wang, W.W.B., Annunziato, P.W., Silber, J.L., . (2005) A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults. New England Journal of Medicine 352:22, 2271-2284
Full Text70
K J Thomson, D P Hart, L Banerjee, K N Ward, K S Peggs, S Mackinnon. (2005) The effect of low-dose aciclovir on reactivation of varicella zoster virus after allogeneic haemopoietic stem cell transplantation. Bone Marrow Transplantation 35:11, 1065-1069
CrossRef71
P Ljungman, D Engelhard, R de la Cámara, H Einsele, A Locasciulli, R Martino, P Ribaud, K Ward, C Cordonnier. (2005) Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT. Bone Marrow Transplantation 35:8, 737-746
CrossRef72
Clarisse M Machado. (2005) Reimmunization after hematopoietic stem cell transplantation. Expert Review of Vaccines 4:2, 219-228
CrossRef73
A. Geel, W. Zuidema, T. van Gelder, G. van Doornum, W. Weimar. (2005) Successful Vaccination Against Varicella Zoster Virus Prior to Kidney Transplantation. Transplantation Proceedings 37:2, 952-953
CrossRef74
Joseph H. Antin, Eva C. Guinan, David Avigan, Robert J. Soiffer, Robin M. Joyce, Victoria J. Martin, Deborah C. Molrine. (2005) Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation 11:3, 213-222
CrossRef75
(2004) Herpes Simplex Virus (HSV)-1 and -2, and Varicella Zoster Virus (VZV). American Journal of Transplantation 4:s10, 69-71
CrossRef76
Ana Marli Christovam Sartori. (2004) A review of the varicella vaccine in immunocompromised individuals. International Journal of Infectious Diseases 8:5, 259-270
CrossRef77
Ting-Fan Leung, Chi-Kong Li, Emily C. W. Hung, Paul K. S. Chan, Chi-Wai Mo, Raymond P. O. Wong, Ki-Wai Chik. (2004) Immunogenicity of a two-dose regime of varicella vaccine in children with cancers. European Journal of Haematology 72:5, 353-357
CrossRef78
A.C.M Boon, S Plotkin, G.F Rimmelzwaan, A.D.M.E Osterhaus. (2004) Viral Vaccine meeting held in Barcelona, October 25–28, 2003. Vaccine 22:11-12, 1327-1334
CrossRef79
Sita Gourishankar, Jill C. McDermid, Gian S. Jhangri, Jutta K. Preiksaitis. (2004) Herpes Zoster Infection Following Solid Organ Transplantation: Incidence, Risk Factors and Outcomes in the Current Immunosuppressive Era. American Journal of Transplantation 4:1, 108-115
CrossRef80
Mark W Douglas, Robert W Johnson, Anthony L Cunningham. (2004) Tolerability of Treatments for Postherpetic Neuralgia. Drug Safety 27:15, 1217-1233
CrossRef81
Hitoshi Sato, Jun-ichi Yamamura, Seiji Kageyama, Masahiko Kurokawa, Kimiyasu Shiraki. (2003) Superiority of varicella skin test antigen over purified varicella-zoster virus glycoproteins in monitoring booster response to Oka varicella vaccine. Vaccine 22:1, 15-20
CrossRef82
Tetsushi Yoshikawa. (2003) Significance of human herpesviruses to transplant recipients. Current Opinion in Infectious Diseases 16:6, 601-606
CrossRef83
Maha Almuneef, Joanne Dillon, Moustafa F. Abbas, Ziad Memish. (2003) Varicella zoster virus immunity in multinational health care workers of a Saudi Arabian hospital. American Journal of Infection Control 31:6, 375-381
CrossRef84
Michiaki Takahashi, Shintaro Okada, Hiromi Miyagawa, Kiyoko Amo, Kunihiko Yoshikawa, Hideo Asada, Hitoshi Kamiya, Sadayoshi Torigoe, Yoshizo Asano, Takao Ozaki, Kibhei Terada, Ryoichi Muraki, Kazbuo Higa, Hiroshi Iwasaki, Masataka Akiyama, Akihisa Takamizawa, Kimibyasu Shiraki, Kazuo Yanagi, Koichi Yamanishi. (2003) Enhancement of immunity against VZV by giving live varicella vaccine to the elderly assessed by VZV skin test and IAHA, gpELISA antibody assay. Vaccine 21:25-26, 3845-3853
CrossRef85
Karen MJ Douglas, Caroline Gordon, Husam Osman, Stephanie Heaton, Jan Skan, Deva Situnayake, Simon J Bowman. (2003) Lupus and zoster. The Lancet 362:9384, 616
CrossRef86
Jay A. Fishman. (2003) Smallpox and Live-Virus Vaccination in Transplant Recipients. American Journal of Transplantation 3:7, 786-793
CrossRef87
P.L. Mackie. (2003) The classification of viruses infecting the respiratory tract. Paediatric Respiratory Reviews 4:2, 84-90
CrossRef88
(2002) Varicella Vaccine in Recipients of Hematopoietic-Cell Transplants. New England Journal of Medicine 347:20, 1624-1625
Full Text89
Antin, Joseph H., . (2002) Long-Term Care after Hematopoietic-Cell Transplantation in Adults. New England Journal of Medicine 347:1, 36-42
Full Text
- Letters
